GHK-Cu (Copper Peptide)
ContestedTissue Repair / Cosmetic
Our read of public sources: some pharmacies compound it under a legal theory — a differentiated-formulation argument, or in anticipation of a pending committee recommendation — that no court ruling or final FDA rule has settled either way. We're flagging this as actively debated, not as a green or red light. This is not a legal determination; verify independently before relying on it.
Not legal advice. Every status on this page is our own reading of public FDA guidance, shortage listings, and committee materials — it has not been reviewed by an attorney and is not a legal determination. "Contested" means pharmacies and regulators publicly disagree, not that we're resolving the disagreement. Verify independently, and check with counsel, before relying on any entry here.
Current status
Formulation-dependent: non-injectable GHK-Cu (topical creams, serums, sprays) sits in Category 1 of FDA's 503A bulk substances review — substances under evaluation — and is compoundable under the interim enforcement policy with a valid patient-specific prescription. Injectable GHK-Cu is not covered by that same allowance and is generally treated as having no established compounding pathway.
Last changed: 2026-01-01